ClinicalTrials.gg
CompletedNCT01495013Updated Nov 21, 2016

A Comparison of Atorvastatin and Glimepiride Fixed Dose Combination and Atorvastatin and Glimepiride Loose Combination in the Treatment of Patients With Type 2 Diabetes Mellitus

A Phase 3 interventional study of 1mg Glimepiride/10mg Atorvastatin FDC and 2mg Glimepiride/10mg Atorvastatin FDC in Diabetes Mellitus, Type 2, sponsored by GlaxoSmithKline. Completed at 33 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-21.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
427
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 52 studies testing glimepiride in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, 1 of them phase 3. glimepiride · Diabetes Mellitus, Type 2.

Enrollment
11th of 52
427 · median 169
Started
2011
with 2 others
Phase 3
18 of 52
1 open now
Registered
29th of 52
by date
Lead sponsor
2 of 52
GlaxoSmithKline

Among the 52 studies testing glimepiride in Diabetes Mellitus, Type 2, this one is the 11th largest by enrollment, is one of 3 that started in 2011, is one of 18 in phase 3, and was the 29th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

1 of the 52 studies testing glimepiride in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About glimepiride

glimepiride: first FDA approval 1995 (AMARYL), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies testing glimepiride in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The aim of this 20 week study is to show that glimepiride/atorvastatin fixed dose combination tablet is safe and as effective as atorvastatin + glimepiride combination taken as separate tablets, in improving glycaemic control (glycated haemoglobin, HbA1c) and cholesterol levels (Low-density lipoprotein, LDL) in diabetic subjects, who are inadequately controlled on a stable dose of metformin. Eight dose combinations will be included.

Read the detailed description

Patients diagnosed with Type 2 diabetes (T2D) are initially provided with lifestyle advice in order to manage the condition by diet, exercise and weight reduction, followed by treatment with metformin. However, many patients do not gain adequate control of fasting glucose by these methods and other anti-diabetic agents are needed. Furthermore, these patients have an increased cardiovascular risk compared with the general population. Approximately one half of patients with T2D die prematurely of a cardiovascular cause and approximately 10% die of renal failure.

Atherogenic dyslipidemia, which is defined as the triad of elevated triglycerides, low high-density lipoprotein cholesterol (HDL-C), and small low-density lipoprotein cholesterol (LDL-C) particles, is commonly found in individuals with T2D. In diabetic patients, the LDL particles tend to be smaller, denser, and more atherogenic than in the general population. As a result, in patients with diabetes, lowering LDL-C levels may lead to a greater benefit in terms of Cardiovascular disease (CVD) risk reduction than in patients without diabetes. Multiple clinical trials have demonstrated significant benefits of lipid-lowering (primarily statin) therapy on CVD outcomes for primary and secondary prevention, irrespective of baseline lipid levels. Hence, clinical treatment guidelines recommend that patients with T2D should be treated with both an anti-diabetic agent and a statin.

Glimepiride is an established once-daily sulphonylurea for use as first-line therapy, and is often used in patients who are metformin intolerant, or in those who are failing to achieve glucose control on metformin monotherapy. Atorvastatin is an established statin that is indicated for reducing the risk of cardiovascular events in diabetic patients, without clinically evident coronary heart disease (CHD), irrespective of whether cholesterol is raised. The risk:benefit of both glimepiride and atorvastatin is well established and described in the approved product labels. There is widespread use of both glimepiride and atorvastatin, prescribed separately, in the T2D population. The available literature indicates that there is no drug-drug interaction risk associated with this combination therapy and no clinical PK interactions between atorvastatin and glimepiride have been recorded. A once-daily combination product which combines both glimepiride and atorvastatin will fulfil an unmet clinical need in simplifying patient treatment regimens in a patient population who have a significant disease burden. Providing concurrent access to a statin in patients with T2D, in addition to medication to manage glucose levels, is a critical requirement for ensuring appropriate management of cardio-metabolic risk.

In this study, subjects already on a stable dose of metformin will be randomised to either to receive the glimepiride/atorvastatin fixed dose combination treatment or atorvastatin + glimepiride combination taken as separate tablets. The starting dose for all subjects will be 1mg glimepiride and 10mg atorvastatin. The glimepiride dose will be titrated up if the average fasting glucose is >7.0mmol/L. The atorvastatin dose will be titrated up if LDL is >2.6mmol/L.

The purpose of the study is to demonstrate non-inferiority of the glimepiride/atorvastatin fixed dose combination compared with glimepiride +atorvastatin taken as separate tablets in reducing HbA1c and LDL.

03

Conditions studied

  • Diabetes Mellitus, Type 2

Keywords

  • non-inferiority
  • glimepiride
  • LDL cholesterol
  • fixed dose combination
  • atorvastatin
  • Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult (≥18 years of age) males and females ( including of ) with Type 2 diabetes mellitus.
  • Currently treated for Type 2 daibetes mellitus with metformin monotherapy and have been a stable dose of metformin for atleast 3 months
  • patients with CVD or ≥40 years old with a cardiovascular risk factor, or \<40 years old with LDL-C level 100mg/dL
  • levels ≥7.0 and \<9.5% at screening or within 3 months prior to study enrollment
  • Fasting blood glucose >7.0 mmol/L on 4 days in a week
  • Statin-naïve or no statin use for 2 months prior to screening
  • Provision of

Exclusion criteria

Exclusion Criteria:

  • Concomitant treatment:
  • Concomitant treatment with statins other than study medication
  • Concomitant treatment with fenofibrate or other lipid lowering agents
  • concomitant treatment with anti-diabetic therapy other than study treatment or change in metformin monotherapy for subjects already treated with metformin
  • Concurrent diseases and symptoms:
  • Subjects with Type 1 diabetes or who have a current need for insulin therapy
  • Subjects with symptomatic hyperglycaemia requiring immediate therapy in the judgement of the investigator
  • Subjects with myalgia
  • Significant hypertriglyceridaemia as defined by fasting triglycerides >3.5 mmol/L
  • ongoing cardiovascular disease:
  • Subjects who have had an acute cardiovascular event within 30 days prior to randomisation
  • Subjects with unstable or severe angina, coronary insufficiency or class III-IV heart failure
  • subjects with a prior heart transplant or who are awaiting a heart transplant
  • Subjects with systolic blood pressure >160 mmHg or diastolic blood pressure >90 mmHg while on anti-hypertensive treatment
  • General Health:
  • Subjects with end stage renal disease requiring renal replacement therapy
  • Subjects receiving drug therapy to treat liver disease
  • Subjects with diagnosis of cancer ( other than superficial squamous. basal cell skin cancer or adequately treated cervical carcinoma in situ) in the past 3 years or who are currently receiving treatment for an active cancer ( other than prophylactic)
  • Subjects with a clinically significant abnormality identified at screening on physical examination or laboratory tests (including thyroid stimulating hormone) which, in the judgement of the investigator, would preclude safe completion of the study
  • Subjects with anaemia defined by a concentration \<10 g/dL (100) g/L) for females and \<12 g/dL (120 g/L) for males or a haemoglobinopathy that could interfere with the assessment of
  • Subjects with clinically significant liver disease as defined by ( ALT) or aspartate aminotransferase (AST) levels >2.5 times the (ULN) or a diagnosis of Chronic active hepatitis including that of viral aetiology, or on antiviral or therapy
  • Subjects with to or history of to, the products
  • Subjects who are clinically or medically unstable, with expected survival \<1 year
  • Subjects with a recent history ( within the last 6 months ) or suspicion of current drug abuse or alcohol abuse
  • Any other factor likely to limit protocol compliance or reporting of adverse events
  • Previous study participation:
  • Participation in another clinical trial of an investigational agent, if the subject has used an investigational agent within 30 days or 5 half lives (whichever is longer) preceding the Screening Visit
  • Previous randomisation in this study

:

  • Females of who are not using highly effective methods for avoiding pregnancy. Highly effective methods include:
  • Oral Contraceptive, either combined or progestogen alone
  • Injectable progestogen
  • Implants of levonorgestrel
  • Estrogenic vaginal ring
  • Percutaneous contraceptive patches
  • Intrauterine device or intrauterine system with a failure rate of less than 1% per year
  • Male partner sterilisation (vasectomy with documentation of azoospermia) prior to the female subject's entry into the study, and this male is the sole partner for that subject. For this definition, "documented" refers to the outcome of the investigator's/designee's medical examination of the subject or review of the subject's medical history for study eligibility, as obtained via a verbal interview with the subject or from the subject's medical records
  • Double barrier method: condom and an occlusive cap(diaphragm or cervical/vault caps) with a vaginal spermicidal agent (foam/gel/film/cream/suppository), including nonoxynol-9
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
427 participants (actual)

Study arms

  • Active comparator
    Glimepiride Atorvastatin fixed dose combination

    All subjects will start on 1mg glimepiride/10 mg atorvastatin fixed dose combination (FDC) and either treatment can be titrated up based on fasting glucose or LDL levels. The following glimepiride/atorvastations FDCs will be available for use 1mg/10mg, 2mg/10mg, 3mg/10mg, 4mg/10mg, 1mg/20mg, 2mg/20mg, 3mg/20mg, 4mg/20mg.

    Drug: 1mg Glimepiride/10mg Atorvastatin FDC · Drug: 2mg Glimepiride/10mg Atorvastatin FDC · Drug: 3mg Glimepiride/10mg Atorvastatin FDC · Drug: 4mg Glimepiride/10mg Atorvastatin FDC · Drug: 1mg Glimepiride/20mg Atorvastatin FDC · Drug: 2mg Glimepiride/20mg Atorvastatin FDC · Drug: 3mg Glimepiride/20mg Atorvastatin FDC · Drug: 4mg Glimepiride/20mg Atorvastatin FDC

  • Active comparator
    Glimepiride +Atrovastatin loose combination

    All subjects will start on 1mg glimepiride/10 mg atorvastatin loose combination (given as separate tablets) and either treatment can be titrated up based on fasting glucose or LDL levels. Glimepiride single dose tablets are available for 1mg, 2mg, 3mg and 4mg. Atorvastatin single dose tablets are available for 10mg and 20mg.

    Drug: 1mg Glimepiride · Drug: 2mg Glimepiride · Drug: 3mg Glimepiride · Drug: 4mg Glimepiride · Drug: 10mg Atorvastatin · Drug: 20mg Atorvastatin

Interventions

  • Drug1mg Glimepiride/10mg Atorvastatin FDC

    Drug pages: Glimepiride · Atorvastatin

    1 tablet by mouth once a day

  • Drug2mg Glimepiride/10mg Atorvastatin FDC

    Drug pages: Glimepiride · Atorvastatin

    1 tablet by mouth once a day

  • Drug3mg Glimepiride/10mg Atorvastatin FDC

    Drug pages: Glimepiride · Atorvastatin

    1 tablet by mouth once a day

  • Drug4mg Glimepiride/10mg Atorvastatin FDC

    Drug pages: Glimepiride · Atorvastatin

    1 tablet by mouth once a day

  • Drug1mg Glimepiride/20mg Atorvastatin FDC

    Drug pages: Glimepiride · Atorvastatin

    1 tablet by mouth once a day

  • Drug2mg Glimepiride/20mg Atorvastatin FDC

    Drug pages: Glimepiride · Atorvastatin

    1 tablet by mouth once a day

  • Drug3mg Glimepiride/20mg Atorvastatin FDC

    Drug pages: Glimepiride · Atorvastatin

    1 tablet by mouth once a day

  • Drug4mg Glimepiride/20mg Atorvastatin FDC

    Drug pages: Glimepiride · Atorvastatin

    1 tablet by mouth once a day

  • 1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily

  • 1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily

  • 1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily

  • 1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily

  • 1 tablet of Atorvastatin and 1 tablet of Glimepiride co-administered once daily

  • 1 tablet of Atorvastatin and 1 tablet of Glimepiride co-administered once daily

06

What researchers measure

Primary outcomes

  1. Non inferiority of glimepiride/atorvastatin compared with glimepiride + atorvastatin taken as separate tablets in reducing HbA1c levels

    Change from baseline

    Time frame: Week 20

  2. Non inferiority of glimepiride/atorvastatin compared with glimepiride + atorvastatin taken as separate tablets in reducing LDL levels

    Change from baseline

    Time frame: Week 20

07

Study locations

33 sites
  • GSK Investigational Site
    Bucheon, 134 727, Korea, Republic of
  • GSK Investigational Site
    Busan, 602-739, Korea, Republic of
  • GSK Investigational Site
    Kangwondo, 220-701, Korea, Republic of
  • GSK Investigational Site
    Seocho-ku, Seoul, 137-701, Korea, Republic of
  • GSK Investigational Site
    Seongnam-si Gyeonggi-do, 463-707, Korea, Republic of
  • GSK Investigational Site
    Seoul, 110-744, Korea, Republic of
  • GSK Investigational Site
    Seoul, 110-746, Korea, Republic of
  • GSK Investigational Site
    Seoul, 135-710, Korea, Republic of
  • GSK Investigational Site
    Seoul, 138-736, Korea, Republic of
  • GSK Investigational Site
    Seoul, 139-872, Korea, Republic of
  • GSK Investigational Site
    Seoul, 152-703, Korea, Republic of
  • GSK Investigational Site
    Suwon, 463442, Korea, Republic of
  • GSK Investigational Site
    Ipoh, 30450, Malaysia
  • GSK Investigational Site
    Johor Bahru, 80100, Malaysia
  • GSK Investigational Site
    Kuala Lumpur, 59100, Malaysia
  • GSK Investigational Site
    Kubang Kerian, 16150, Malaysia
  • GSK Investigational Site
    Cuernavaca, 62250, Mexico
  • GSK Investigational Site
    Del. Cuauhtémoc, 06700, Mexico
  • GSK Investigational Site
    Gadalajara, Jalisco, C.P. 44130, Mexico
  • GSK Investigational Site
    Guadalajara Jalisco, C.P. 44210, Mexico
  • GSK Investigational Site
    Mexico City, 06700, Mexico
  • GSK Investigational Site
    Mexico, D.F., 11650, Mexico
  • GSK Investigational Site
    Cebu City, 6000, Philippines
  • GSK Investigational Site
    Davao City, 8000, Philippines
  • GSK Investigational Site
    Manila, 1008, Philippines
  • GSK Investigational Site
    Pasig City, 1600, Philippines
  • GSK Investigational Site
    Sta. Cruz, Manila, 1012, Philippines
  • GSK Investigational Site
    Moscow, 109240, Russian Federation
  • GSK Investigational Site
    Saratov, 410054, Russian Federation
  • GSK Investigational Site
    St. Petersburg, 191119, Russian Federation
  • GSK Investigational Site
    Chiangrai, 57000, Thailand
  • GSK Investigational Site
    Nakhon Ratchasima, 30000, Thailand
  • GSK Investigational Site
    Rajathevee, 10400, Thailand
08

References and documents

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2011, a primary completion of Apr 2013 and a completion of Sep 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2011
First posted
Dec 19, 2011
Start
Dec 2011
Primary completionActual
Apr 2013
CompletionActual
Sep 2013
Results delay requested
Mar 6, 2014
Last update
Nov 21, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01495013
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Dec 19, 2011
Start date
Dec 2011
Primary completion
Apr 2013
Completion
Sep 2013
Last update
Nov 21, 2016

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Glimepiride · Atorvastatin

Start the discussion